Brief: Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design Of TERN-701 For The Treatment Of Chronic Myeloid Leukemia
16/10/2023 14:05
Oct 16 (Reuters) - Terns Pharmaceuticals Inc TERN.O :
* TERNS PHARMACEUTICALS ANNOUNCES GLOBAL PHASE 1 CLINICAL
TRIAL
DESIGN OF TERN-701 FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA
* TERNS PHARMACEUTICALS INC - PATIENT SCREENING ANTICIPATED
IN
DECEMBER 2023, WITH INITIAL DATA EXPECTED IN SECOND HALF OF 2024
* TERNS PHARMACEUTICALS INC - INVESTIGATIONAL NEW DRUG
APPLICATION
CLEARED BY U.S. FOOD AND DRUG ADMINISTRATION
Source text for Eikon: ID:nGNX6qt5NW
Further company coverage: TERN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Terns Pharmaceuticals
See all newsNASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP-East West Bancorp, Reliance, S&P Global
Brief: Merck Announces Expiration Of Hart-Scott-Rodino Act Waiting Period To Acquire Terns Pharmaceuticals
Brief: Merck Begins Tender Offer To Acquire Terns Pharmaceuticals, Inc.